Suppr超能文献

相似文献

1
Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.
Am J Obstet Gynecol. 2009 Apr;200(4):457.e1-5. doi: 10.1016/j.ajog.2008.12.012. Epub 2009 Feb 6.
2
Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma.
Am J Obstet Gynecol. 2010 Sep;203(3):242.e1-5. doi: 10.1016/j.ajog.2010.04.046. Epub 2010 Jun 3.
3
Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report.
Pathol Res Pract. 2008;204(3):203-7. doi: 10.1016/j.prp.2007.11.009. Epub 2008 Jan 18.
5
Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma.
Ann Surg Oncol. 2013 Jul;20(7):2373-9. doi: 10.1245/s10434-012-2838-9. Epub 2013 Jan 24.
7
Prognostic factors and status of hormone receptors and angiogenic factors in uterine carcinosarcoma.
J Obstet Gynaecol Res. 2014 Mar;40(3):820-5. doi: 10.1111/jog.12251. Epub 2013 Dec 10.
8
Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas.
Int J Gynecol Cancer. 2018 Mar;28(3):500-504. doi: 10.1097/IGC.0000000000001183.
9
Nestin: A biomarker of aggressive uterine cancers.
Gynecol Oncol. 2016 Mar;140(3):503-11. doi: 10.1016/j.ygyno.2015.12.015. Epub 2015 Dec 21.
10
Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Gynecol Oncol. 2007 Apr;105(1):138-44. doi: 10.1016/j.ygyno.2006.11.001. Epub 2006 Dec 18.

引用本文的文献

1
Challenges in Differentiating Uterine Mesenchymal Tumors-Key Diagnostic Criteria.
J Clin Med. 2025 Jul 1;14(13):4644. doi: 10.3390/jcm14134644.
2
Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine Carcinosarcoma.
Curr Oncol. 2022 Oct 13;29(10):7607-7623. doi: 10.3390/curroncol29100601.
3
cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma.
Turk Patoloji Derg. 2023;39(1):55-63. doi: 10.5146/tjpath.2022.01588.
4
Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas.
Int J Gynecol Cancer. 2018 Mar;28(3):500-504. doi: 10.1097/IGC.0000000000001183.
6
The biology of uterine sarcomas: A review and update.
Mol Clin Oncol. 2013 Jul;1(4):599-609. doi: 10.3892/mco.2013.124. Epub 2013 May 20.
7
Estrogen receptors and human disease: an update.
Arch Toxicol. 2012 Oct;86(10):1491-504. doi: 10.1007/s00204-012-0868-5. Epub 2012 May 31.
10
Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma.
Am J Obstet Gynecol. 2010 Sep;203(3):242.e1-5. doi: 10.1016/j.ajog.2010.04.046. Epub 2010 Jun 3.

本文引用的文献

1
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.
Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):921-9. doi: 10.1158/1055-9965.EPI-07-2686.
2
4
Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.
Gynecol Oncol. 2007 Dec;107(3):513-7. doi: 10.1016/j.ygyno.2007.08.060. Epub 2007 Oct 23.
6
Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Gynecol Oncol. 2007 Apr;105(1):138-44. doi: 10.1016/j.ygyno.2006.11.001. Epub 2006 Dec 18.
8
Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis.
Nat Rev Cancer. 2006 May;6(5):360-8. doi: 10.1038/nrc1879.
9
Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors.
Am J Obstet Gynecol. 2006 Apr;194(4):1119-26; discussion 1126-8. doi: 10.1016/j.ajog.2005.12.020.
10
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Gynecol Oncol. 2006 Jan;100(1):101-6. doi: 10.1016/j.ygyno.2005.07.124. Epub 2005 Sep 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验